

# **Economic Insight**

Analyst: Andy Yao Shaohua, PhD Tel: 852-2147 8863

Email: yaoshaohua@abci.com.hk

# China's trade stayed strong in Mar

**ABCI** Research

April 14, 2021

- In USD terms, China's Mar exports grew 30.6%, thanks to the increase in external demand supported by the gradual recovery of the world's major economies from the pandemic due to vaccination and the low base effect
- Import growth rebounded sharply to 38.1% in Mar from 22.2% in the first two months in USD terms. The rebound in imports in Mar was mainly attributable to the accelerating growth in domestic demand and the sharp rebound in international commodity prices, in addition to the low base last year
- As imports grew faster in Mar, trade surplus fell to US\$ 13.8bn in Mar. However, due to the high trade surplus recorded in the first two months, the trade surplus in 1Q21 reached US\$ 116.4bn, up by a drastic 781.8%. The net exports of goods and services in 1Q21 have brought solid support to China's economic growth
- Looking ahead, we estimate export growth will gradually decline due to the higher base and further recovery of the overseas supply chain. Import growth will maintain an uptrend due to the high commodity prices and strengthening domestic demand; consequently, trade surplus may narrow

China's Mar export growth was down from the exceptionally high at 60.6%¹ in 2M21 to 30.6% in USD terms - a substantial increase nonetheless (Exhibit 1). The rapid export growth was in line with the advancement observed in the new export orders index within the official manufacturing PMI in Mar. The export growth was largely driven by a reviving external demand from the world's major economies, thanks to the vaccination rollout, as well as the low base in 2020. Data shows that the manufacturing PMI of the US, the Eurozone, and Japan rose to 64.7, 62.5, and 52.7 in Mar, which in turn propped up China's exports. In addition, the spot CNY against USD depreciated by an average of 0.6% in Mar compared with the previous two months, which also supported China's exports. China's export growth in Mar is still robust excluding the base effect. Compared with Mar 2019, China's exports in Mar increased by 21.3%, indicating an average growth of 10.3% in two years.

China's export shipment to five major destinations – the ASEAN, EU, the US, Hong Kong, and Japan, grew by 14.4%, 45.9%, 53.3%, 33.3%, and 7.6%, respectively, in Mar. China's exports to main markets, especially the US, have stayed high, reflecting that the new round of the US rescue plan has increased the demand for Chinese goods. It is worth noting that the export of anti-epidemic products slowed in Mar - export growth of plastic products in Mar was 22.5%, that of textile yarn, fabric and products was 8.4%, and that of medical instruments and devices was 39.0%; conversely, the export growth of integrated circuits rebounded to 33.0% in Mar from 30.8% in the first two months.

All growth rates are year-on-year except specified otherwise



80.0 60.0 40.0 20.0 0.0 (20.0)(40.0)06/2020 02/2021 02/2020 04/2020 08/2020 10/2020 12/2020 imports growth exports growth

Exhibit 1: China's export and import growth (%)

Source(s): China Customs, ABCI Securities

Import growth rebounded sharply to 38.1% in Mar from 22.2% in the first two months in USD terms, well above the consensus forecast of a 24.4% increase. Excluding the base effect, imports in Mar this year increased by 36.9% over Mar 2019, implying an average increase of 16.7% over the two years. Import growth from the US advanced to 75.1% in Mar from 66.4% in 2M21. The rebound in imports in Mar was mainly attributable to the accelerating growth in domestic demand and the sharp rebound in international commodity prices, in addition to the low base in 2020. Excluding the price factor, the import growth of major commodities all rose sharply in Mar by import volume, thanks to the reviving domestic demand. By volume, imports of crude oil, iron ore, integrated circuits, soybeans, and grains grew 20.8%, 18.9%, 30.0%, 81.5%, and 87.0%, respectively.

Due to the strong import growth in Mar, trade surplus fell to US\$ 13.8bn for the month, much lower than the market expectation of US\$ 52bn. However, due to the high trade surplus recorded in 2M21, trade surplus in 1Q21 reached US\$ 116.4bn, up 781.8% YoY. Net exports of goods and services in 1Q21 have brought support to China's economic growth. Notably, the country's trade surplus with the US was as high as US\$ 21.4bn in Mar.

Looking ahead, with the gradual increase of the base last year and the further recovery of overseas supply chains, we expect China's export growth may gradually decline. Imports are likely to maintain a strong growth with the strengthening of domestic demand and the rising international commodity prices; consequently, we expect trade surplus to narrow further.



## **Disclosures**

### **Analyst Certification**

I, Yao Shaohua, Andy, being the person primarily responsible for the content of this research report, in whole or in part, hereby certify that all of the views expressed in this report accurately reflect my personal view about the subject company or companies and its or their securities. I also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I and/or My associates have no financial interests in relation to any listed company (ies) covered in this report, and I and/or My associates do not serve as officer(s) of any listed company (ies) covered in this report.

**Definition of equity rating** 

Rating	Definition
Buy	Stock return rate≥ Market return rate (~10%)
Hold	- Market return rate (~-10%) ≤ Stock return rate < Market return rate (~10%)
Sell	Stock return < - Market return (~-10%)

Notes: Stock return rate: expected percentage change of share price plus gross dividend yield over the next 12 months

Market return rate: average market return rate since 2008 (HSI total return index 2008-20 CAGR at 9.2%)

Time horizon of share price target: 12-month

Stock rating, however, may vary from the stated framework due to factors including but not limited to: corporate governance, market capitalization, historical price volatility relative to corresponding benchmark index, average daily turnover of the stock relative to market capitalization of the stock, competitive advantages in corresponding industry, etc.

#### **Disclaimer**

This report is for our clients only and is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expresses or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein. This report should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. ABCI Securities Company Limited is under no obligation to update or keep current the information contained herein. ABCI Securities Company Limited relies on information barriers to control the flow of information contained in one or more areas within ABCI Securities Company Limited, into other areas, units, groups or affiliates of ABCI Securities Company Limited. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of ABCI Securities Company Limited as a whole, of which investment banking, sales and trading are a part. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of



investors. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither ABCI Securities Company Limited nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

Copyright 2021ABCI Securities Company Limited

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of ABCI Securities Company Limited.

Office address: ABCI Securities Company Limited, 13/F Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong.

Tel: (852) 2868 2183